ProfileGDS5678 / 1423477_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 96% 96% 96% 95% 97% 97% 97% 96% 96% 97% 96% 97% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.0497296
GSM967853U87-EV human glioblastoma xenograft - Control 29.0567596
GSM967854U87-EV human glioblastoma xenograft - Control 39.0583196
GSM967855U87-EV human glioblastoma xenograft - Control 48.9513196
GSM967856U87-EV human glioblastoma xenograft - Control 58.5949995
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 19.2382497
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 29.3333397
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 39.0483697
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.9756196
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.991796
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 29.2460797
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.9989996
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.163897
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.9714596